Trinomab Biotechnology Co Ltd
-
Trinomab’s human monoclonal antibody against tetanus toxin have approved for phase I clinical trial in Australia.
Trinomab Biotechnology Co., Ltd’s domestically developed human monoclonal antibody against tetanus toxin TNM002 has been officially approved by Human Research Ethics Committee (HREC) and Therapeutic Goods Administration (TGA) in Australia for the Phase I clinical trial.
